OakChart

Rezolute Inc

RZLTHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

4.07+0.05 (1.24%)
2026-11-12 02:11 CET
Market cap
388.85 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-77.92 USD m
Free cash flow, TTM
-65.99 USD m
EPS diluted, TTM
-0.75
P/E
-
Compare

Price

RZLT against its 20, 50 and 200-day averages
2050200beatmiss
3.004.005.003.4M6.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RZLTclose 4.0720-day 3.8950-day 4.10200-day 3.924.07

63.5% under the 52-week high of 11.17 on 10 Dec 2025. 52-week low 1.07 on 11 Dec 2025. Last 15 sessions, 21.8% high to low

Volume 0.64× normal · the line is the 50-bar volume average

Profile

RZLT
52-week range, 30% of the way up
1.0711.16

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

IndexRUT
Employees58
IPOMay 08, 2012
Beta0.62
ATR, 14d0.30
Rel volume0.64
Short float22.23%
Insider own13.96%
Inst own95.54%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap393.69M
Enterprise Value304.44M
Income-77.92M
Sales0.00M
Book/sh0.89
Cash/sh0.93
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees58
IPOMay 08, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.58
P/C4.37
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio9.92
Current Ratio9.92
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.75
EPS next Y-0.50
EPS next Q-0.17
EPS this Y6.24%
EPS next Y29.52%
EPS next 5Y-
EPS past 3/5Y9.63% 22.81%
Sales past 3/5Y- -
EPS Y/Y TTM19.53%
Sales Y/Y TTM-
EPS Q/Q-0.51%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.2.91% -

Ownership

Insider Own13.96%
Insider Trans0.00%
Inst Own95.54%
Inst Trans4.14%
ROA-61.19%
ROE-66.85%
ROIC-90.55%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA204.57%
SMA50-0.77%
SMA2003.84%
Trades-

Technical

Shs Outstand96.72M
Shs Float83.22M
Short Float22.23%
Short Ratio12.20
Short Interest18.50M
52W High11.16 -63.55%
52W Low1.07 280.37%
Volatility8.56% 8.00%
ATR (14)0.30
RSI (14)51.48
Beta0.62
Rel Volume0.64
Avg Volume1.52M
Volume974,257

Performance

Perf Week2.78%
Perf Month-11.71%
Perf Quarter-11.52%
Perf Half Y22.22%
Perf YTD72.46%
Perf Year-59.46%
Perf 3Y435.46%
Perf 5Y-34.57%
Perf 10Y-92.73%
Recom1.00
Target Price10.10
Prev Close4.02
Price4.07
Change %1.24%

Analyst ratings

latest 10 of 18
DateActionAnalystRating changeTargetImplied
Oct 06, 2026UpgradeCCantor FitzgeraldNeutral → Overweight
Sep 30, 2026InitiatedLLake StreetBuy$9+121.1%
Sep 29, 2026UpgradeCCraig HallumHold → Buy$7+72.0%
Jun 03, 2026UpgradeCCitizensMkt Perform → Mkt Outperform$11+170.3%
Mar 25, 2026UpgradeWWedbushNeutral → Outperform$5+22.9%
Dec 11, 2025DowngradeWWedbushOutperform → Neutral$1-75.4%
Dec 11, 2025DowngradeCCraig HallumBuy → Hold$2-50.9%
Dec 11, 2025DowngradeCCantor FitzgeraldOverweight → Neutral
Nov 05, 2024InitiatedWWedbushOutperform$12+194.8%
Aug 27, 2024InitiatedGGuggenheimBuy$11+170.3%

Peers

Mkt cap
TickerCompanyMkt cap
MBXMBX Biosciences Inc2.87B
AMLXAmylyx Pharmaceuticals Inc4.09B
RYTMRhythm Pharmaceuticals Inc7.78B
XERSXeris Biopharma Holdings Inc3.02B
ASNDAscendis Pharma A/S17.03B
ENTXEntera Bio Ltd560.73M
SPRBSpruce Biosciences Inc132.78M
ETONEton Pharmaceuticals Inc1.97B
NBIXNeurocrine Biosciences Inc17.65B
NVONovo Nordisk ADR137.48B

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Evans DaronCFOMar 30 '26Buy2.8510,00028,500414,462Mar 31 04:59 PM
Hogenhuis WladimirDirectorDec 16 '25Buy1.695,6509,548119,675Dec 17 04:14 PM
ROBERTS BRIAN KENNETHChief Medical OfficerDec 16 '25Buy1.7028,00047,600308,352Dec 17 04:13 PM
Evans DaronCFODec 15 '25Buy1.7740,00070,640415,900Dec 15 07:35 PM
Evans DaronCFODec 15 '25Buy1.795,0008,9387,000Dec 15 07:35 PM
Elam Nevan CCEODec 15 '25Buy1.5932,00050,880641,119Dec 15 07:35 PM
Karnawat Sunil RatilalChief Commercial OfficerDec 15 '25Buy1.6212,10019,59971,542Dec 15 07:34 PM
Evans DaronCFODec 09 '25Buy5.0410,54953,167131,900Dec 10 09:11 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
JSMLJanus Henderson Small Cap Growth Alpha ETFAUM: 377.91M
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update (GlobeNewswire) -8.08% +6.59%
  • Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism (GlobeNewswire) -8.24% -7.80%
  • Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss Retail Expects Huge Rerating (Stocktwits) +7.98%
  • Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism (GlobeNewswire)
  • Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint (InvestorsHub) -7.73%
  • Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism (GlobeNewswire)
  • Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity (FinanceWire)
  • Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire) +14.38%
  • Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society (GlobeNewswire)
  • Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society (GlobeNewswire)
  • Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls (The Fly) +14.50%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2027Q12026-11-05-0.180-0.185-0.1800.000.0010
2026Q42026-09-24-0.200-0.148-0.1960.000.0010
2026Q32026-05-12-0.160-0.181-0.1550.000.009
2026Q22026-02-12-0.220-0.187-0.2200.000.0010
2026Q12025-11-06-0.180-0.242-0.1760.000.006
2025Q42025-09-17-0.260-0.219-0.2590.000.0010
2025Q32025-05-13-0.270-0.229-0.2700.000.009
2025Q22025-02-12-0.220-0.250-0.2250.000.0010
2025Q12024-11-07-0.220-0.333-0.2210.000.007
2024Q42024-09-19-0.440-0.318-0.4400.000.0010
2024Q32024-05-15-0.340-0.301-0.3360.000.007
2024Q22024-02-13-0.270-0.303-0.2710.000.003
2024Q12023-11-13-0.280-0.283-0.2830.000.004
2023Q42023-09-14-0.250-0.356-0.2480.000.005
2023Q32023-05-11-0.300-0.303-0.3050.000.004
2023Q22023-02-10-0.260-0.318-0.2640.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-3.540-4.000-3.5360.000.00
2021FY-2.720-2.880-2.7250.000.00
2022FY-2.320-2.412-2.3160.000.00
2023FY-1.010-1.128-1.0120.000.00
2024FY-1.330-1.220-1.3300.000.00
2025FY-0.980-0.923-0.9790.000.00
2026FY-0.750-0.700-0.7500.000.00
2027FY--0.703--2.56
2028FY--0.496--55.20
2029FY-0.194--169.16
2030FY-1.495--363.38
2031FY-2.550--554.57

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q2S2026-11-068000.000.000.00
2027Q2S2026-10-028000.000.000.00
2027Q2S2026-09-297000.000.000.00
2027Q2S2026-09-286000.000.000.00
2027Q2S2026-09-255000.000.000.00
2027Q2S2026-05-135000.000.000.00
2027Q2S2026-03-235000.000.000.00
2027Q2S2026-02-194000.000.000.00
2027Q2S2026-02-135001.170.005.84
2027Q2S2025-11-114001.460.005.84
2027Q2S2025-11-103000.000.000.00
2027Q2S2025-11-093000.000.000.00
2027Q2S2025-11-083000.000.000.00
2027Q2S2025-11-073000.000.000.00

Estimate history

EPS, annual-26.828-18.408-3.536-2.725-2.316-1.012-1.33-0.979-0.747-0.7476
Period201820192020202120222023202420252026TTM
EPS, quarterly-0.221-0.225-0.27-0.259-0.176-0.22-0.155-0.196-0.176
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Sales, annual0000000000
Period201820192020202120222023202420252026TTM
Sales, quarterly000000000
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Shares, annual1.2434.2085.8678.35233.58236.82753.24686.99696.40696.722
Period201820192020202120222023202420252026MRQ
Shares, quarterly55.39460.53560.54386.99691.03795.54896.29296.40696.722
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.030.030.040.380.260.010.020.05
Gross Profit-0.03-0.03-0.03-0.04-0.38-0.26-0.01-0.02-0.05
Selling, General and Administrative Excl. Other82.5082.9479.8670.3955.6141.5922.8820.5025.85
Research and Development53.4653.8061.5355.7443.8132.4914.9914.4519.08
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-82.53-82.97-79.89-70.42-55.99-41.84-22.89-20.52-25.90
Interest Expense0.000.000.000.000.001.810.380.004.96
Unusual Expense-0.49-0.500.002.910.01-2.51-2.300.00-0.21
Net Income Before Taxes-77.92-77.59-74.41-68.46-51.79-41.06-20.90-20.33-30.45
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-77.92-77.59-74.41-68.46-51.79-41.06-20.90-20.33-30.45
Net Income From Continuing Operations-77.92-77.59-74.41-68.46-51.79-41.06-20.90-20.33-30.45
Net Income-77.92-77.59-74.41-68.46-51.79-41.06-20.90-20.33-32.72
EPS (Recurring)-0.75-0.75-0.98-1.29-1.01-2.41-2.94-3.54-18.49
EPS (Basic, Before Extraordinaries)-0.75-0.75-0.98-1.33-1.01-2.26-2.72-3.54-18.41
EPS (Diluted)-0.75-0.75-0.98-1.33-1.01-2.32-2.72-3.54-18.41
EBITDA-82.50-82.94-79.86-70.39-55.61-41.59-22.88-20.50-25.85
Non-Operating Income (Expense)4.124.885.484.874.210.080.060.190.20
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.2014.467.127.367.273.693.963.322.64
Shares Outstanding96.7296.4187.0053.2536.8333.588.355.874.21
Market Capitalization388.85388.85387.19220.9672.92108.47119.1927.2812.25

Income statement, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q42025Q32025Q2
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.010.010.010.01
Gross Profit-0.01-0.01-0.01-0.01-0.01-0.01-0.01-0.01
Selling, General and Administrative Excl. Other19.3821.5517.3624.2119.8125.8420.0217.07
Research and Development12.8114.8911.4114.3513.1520.8615.2812.63
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-19.39-21.56-17.37-24.22-19.82-25.85-20.02-17.08
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.02-0.520.000.000.01-0.010.01-0.01
Net Income Before Taxes-18.49-20.49-16.17-22.77-18.15-24.39-18.91-15.73
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-18.49-20.49-16.17-22.77-18.15-24.39-18.91-15.73
Net Income From Continuing Operations-18.49-20.49-16.17-22.77-18.15-24.39-18.91-15.73
Net Income-18.49-20.49-16.17-22.77-18.15-24.39-18.91-15.73
EPS (Recurring)-0.18-0.20-0.16-0.22-0.18-0.26-0.27-0.22
EPS (Basic, Before Extraordinaries)-0.18-0.20-0.16-0.22-0.18-0.26-0.27-0.22
EPS (Diluted)-0.18-0.20-0.16-0.22-0.18-0.26-0.27-0.22
EBITDA-19.38-21.55-17.36-24.21-19.81-25.84-20.02-17.07
Non-Operating Income (Expense)0.920.561.201.451.681.451.111.34
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.274.104.423.412.532.371.911.45
Shares Outstanding96.7296.4196.2995.5591.0487.0060.5460.53
Market Capitalization393.69500.72291.88218.84853.63387.19175.55283.92

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments107.80167.86126.87101.90150.4141.059.9611.571.65
Short Term Receivables0.500.700.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.212.591.783.011.690.950.560.570.36
Total Current Assets110.51171.15128.65104.91152.1041.9910.5212.142.01
Net Property, Plant & Equipment0.811.421.982.190.170.420.420.040.37
Total Investments and Advances0.000.000.2616.470.000.000.000.000.00
Intangible Assets----0.000.000.000.030.04
Other Assets1.532.921.840.150.150.190.030.040.09
Total Assets112.85175.49132.74123.72152.4242.6110.9612.252.50
Short Term Debt Incl. Current Port. of LT Debt0.660.630.570.540.110.270.240.013.43
Accounts Payable5.035.814.903.271.131.030.891.051.71
Other Current Liabilities5.735.474.141.391.220.672.097.321.11
Total Current Liabilities11.4211.919.615.202.461.973.238.386.25
Long Term Debt0.280.981.661.940.0814.150.170.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.470.470.470.410.410.390.212.120.22
Total Liabilities12.1613.3611.737.552.9516.513.6010.506.46
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity100.69162.13121.00116.17149.4726.107.371.75-3.96
Total Shareholders Equity100.69162.13121.00116.17149.4726.107.371.75-3.96
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity100.69162.13121.00116.17149.4726.107.371.75-3.96
Total Liabilities & Stockholders Equity112.85175.49132.74123.72152.4242.6110.9612.252.50
Book Value Per Share1.041.862.273.154.453.121.260.42-3.19
Tangible Book Value Per Share1.041.862.273.154.453.121.260.41-3.22
Full-Time Employees587159514226231921
Price to Book Ratio4.523.272.440.630.734.573.70-0.4645.66
Return on Assets-53.82-48.28-53.39-37.51-42.11-78.03-175.16-412.69-454.80
Return on Equity-59.04-52.56-57.73-38.99-46.77-124.92-446.05--1,307.66
Return on Invested Capital-76.85-45.62-55.81-43.85-27.46-51.93-270.03-1,737.79-
Quick Ratio9.6814.3713.3920.1861.7821.343.261.450.32
Current Ratio9.6814.3713.3920.1861.7821.343.261.450.32

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-77.92-77.59-74.41-68.46-51.79-41.06-20.90-20.33-30.45
Depreciation0.030.030.030.040.380.260.010.020.05
Other Funds (Non Cash)13.6712.595.267.965.901.832.573.646.74
Funds from Operations-64.22-64.97-69.12-60.47-45.50-38.97-18.32-16.67-23.66
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.760.330.053.101.02-0.64-2.12-7.498.36
Cash from Operating Activities-65.99-64.64-69.08-57.37-44.48-39.62-20.44-24.17-15.30
Capital Expenditures0.000.000.000.00-0.150.000.000.00-0.05
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.28
Purchase or Sale of Investments63.16-21.10-14.5448.70-101.310.000.000.000.00
Purchase of Investments-109.42-178.18-128.14-66.40-107.310.000.000.000.00
Sale Or Maturity of Investments172.58157.08113.60115.106.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities63.16-21.10-14.5448.70-101.460.000.000.000.23
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1.882.24107.3363.0311.57165.2537.2722.550.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock1.882.24107.3363.0311.57165.2537.2722.550.00
Proceedsfrom Stock Options0.00-0.04106.4362.8011.57165.2537.2722.550.00
Issuance or Reduction of Debt, Net0.000.000.000.000.00-16.0115.000.000.00
Change in Long Term Debt0.000.000.000.000.00-16.0115.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.0015.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00-16.010.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.000.00-0.25-0.740.0025.00
Other Financing Activities Uses0.000.000.00-0.000.00-0.25-0.740.000.00
Cash from Financing Activities1.882.24107.3363.0311.57148.9851.5322.5525.00
Net Change in Cash-0.95-83.4923.7154.36-134.37109.3631.09-1.629.93
Free Cash Flow-65.99-64.64-69.08-57.37-44.63-39.62-20.44-24.17-15.35
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Cash & Short Term Investments90.00107.80120.27132.94152.19167.86
Short Term Receivables0.000.500.600.600.000.70
Inventories0.000.000.000.000.000.00
Other Current Assets3.832.211.181.572.512.59
Total Current Assets93.83110.51122.05135.11154.71171.15
Net Property, Plant & Equipment0.650.810.971.121.271.42
Total Investments and Advances0.000.000.000.000.000.00
Other Assets1.531.532.442.402.682.92
Total Assets96.01112.85125.46138.63158.66175.49
Short Term Debt Incl. Current Port. of LT Debt0.640.660.670.670.650.63
Accounts Payable2.185.033.193.783.265.81
Other Current Liabilities6.645.733.845.086.305.47
Total Current Liabilities9.4611.427.709.5310.2111.91
Long Term Debt0.110.280.440.620.800.98
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.490.470.480.480.480.47
Total Liabilities10.0612.168.6210.6311.5013.36
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity85.95100.69116.83128.00147.17162.13
Total Shareholders Equity85.95100.69116.83128.00147.17162.13
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity85.95100.69116.83128.00147.17162.13
Total Liabilities & Stockholders Equity96.01112.85125.46138.63158.66175.49
Book Value Per Share0.891.041.211.341.621.86
Tangible Book Value Per Share0.891.041.211.341.621.86
Full-Time Employees-58---71
Price to Book Ratio4.584.292.281.465.043.27
Return on Assets-61.19-53.82-74.01-67.21-54.73-48.28
Return on Equity-66.85-59.04-81.73-74.02-59.23-52.56
Return on Invested Capital-21.48-20.30-13.79-17.71-12.27-14.95
Quick Ratio9.929.6815.8414.1815.1514.37
Current Ratio9.929.6815.8414.1815.1514.37

Cash flow, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Net Income-18.49-20.49-16.17-22.77-18.15-24.39
Depreciation0.010.010.010.010.010.01
Other Funds (Non Cash)2.963.784.082.841.892.16
Funds from Operations-15.52-16.71-12.08-19.93-16.25-22.22
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.273.56-1.66-0.40-1.180.23
Cash from Operating Activities-18.78-13.15-13.73-20.32-17.43-22.00
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments15.7712.3012.2822.81-68.490.35
Purchase of Investments-20.13-25.43-37.02-26.84-88.89-27.45
Sale Or Maturity of Investments35.9037.7349.3049.6520.4027.80
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities15.7712.3012.2822.81-68.490.35
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.550.230.750.360.91101.16
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.550.230.750.360.91101.16
Proceedsfrom Stock Options0.000.000.000.00-0.04101.03
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.550.230.750.360.91101.16
Net Change in Cash-2.46-0.62-0.712.85-85.0179.51
Free Cash Flow-18.78-13.15-13.73-20.32-17.43-

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3022.23%18.5M83.2M1.50M
2026-10-1523.03%19.2M83.2M1.49M
2026-09-3020.09%16.7M83.2M1.48M
2026-09-1520.53%16.8M81.9M1.62M
2026-08-3121.15%17.0M80.4M1.86M
2026-08-1420.17%16.5M81.9M1.80M
2026-07-3120.99%16.9M80.4M1.80M
2026-07-1520.28%16.3M80.4M1.87M
2026-06-3020.41%16.4M80.4M1.81M
2026-06-1517.18%13.8M80.4M2.18M
2026-05-2917.06%13.7M80.4M2.03M
2026-05-1518.14%14.6M80.4M2.15M
2026-04-3016.45%13.7M83.5M2.49M
2026-04-1515.42%12.9M83.5M2.78M
2026-03-3115.92%13.4M83.9M3.44M
2026-03-1320.20%16.9M83.9M4.58M
2026-02-2720.10%16.9M83.9M7.17M
2026-02-1321.39%17.9M83.9M7.10M
2026-01-3025.71%19.0M73.8M6.83M
2026-01-1525.59%18.9M73.8M6.50M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.053.301.5714.9596.000.000.934-0.0110.001
call5.000.000.250.072.1617080.000.330-0.0280.002
call7.500.000.600.103.80757.000.000.231-0.0420.002
put2.500.000.950.052.3681160.00-0.066-0.0110.001
put5.000.051.551.533.69451.000.00-0.670-0.0280.002
put7.502.703.703.823.9470.000.00-0.769-0.0410.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-28SCHEDULE 13GSEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-21DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-02SEC
2026-10-15DRSSEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-07PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-12-02SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-09-2410-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-12SCHEDULE 13GSEC
2026-08-12SCHEDULE 13G/ASEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-06-028-KCurrent report2026-06-02SEC
2026-05-15SCHEDULE 13GSEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-05-11SCHEDULE 13G/ASEC
2026-05-048-KCurrent report2026-05-01SEC
2026-03-314Statement of changes in beneficial ownership of securities2026-03-30SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-248-KCurrent report2026-03-24SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0328.50K100
2026-020000
2026-010000
2025-12260.37K700
2025-110000

Institutional holders

Manager% owned
FEDERATED HERMES, INC.13.49%
RA CAPITAL MANAGEMENT, L.P.9.81%
BlackRock, Inc.8.02%
Opaleye Management Inc.6.54%
BALYASNY ASSET MANAGEMENT L.P.4.84%
VANGUARD CAPITAL MANAGEMENT LLC3.98%
Siren, L.L.C.3.46%
JACOBS LEVY EQUITY MANAGEMENT, INC2.66%
JENNISON ASSOCIATES LLC2.55%
GEODE CAPITAL MANAGEMENT, LLC2.21%

Funds

Fund% owned
Federated Hermes Kaufmann Fund7.77%
Federated Hermes Kaufmann Small Cap Fund5.55%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.85%
iShares Russell 2000 ETF2.15%
VANGUARD EXTENDED MARKET INDEX FUND1.04%
Fidelity Small Cap Index Fund0.89%
VANGUARD EXPLORER FUND0.77%
iShares Russell 2000 Value ETF0.66%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND0.65%
VANGUARD RUSSELL 2000 INDEX FUND0.47%

OakChart. RZLT. Cached 15 minutes.